×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!
   

Accelerated Pathways: Global Opportunities and Challenges For Innovators

August 23, 2017

Accelerated Pathways (APs) for the development of new drugs have multiplied in recent years and have proven to present opportunities and benefits for patients and developers. But the varied nature and diversity of the accelerated pathways in these jurisdictions are generating new, unanticipated challenges that sponsors need to understand and plan for strategically.

In general, APs in all three regions offer the opportunity for shorter clinical development and/or review times, meaning that drugs can reach markets and patients faster, and developers can generate earlier revenue streams to invest in future research, as well as support necessary post-approval clinical and real-world evidence (RWE) collection, while gaining (in many cases) first-to-market competitive advantages.

The similarities among the opportunities and benefits provided by APs in the U.S., Europe, and Japan, come along with important differences. That, combined with varied pre-approval data requirements for different AP pathways in different jurisdictions, and a growing number of involved stakeholders focusing on the risks and benefits of new products, is adding unanticipated complexity to an already tortuous road to market for new drugs.

Previous Article
Accelerated Pathways & Commercial Consequences Forum & Findings
Accelerated Pathways & Commercial Consequences Forum & Findings

Read this presentation to find out more!

Next Flipbook
Commercial Consequences Of Expedited Approval
Commercial Consequences Of Expedited Approval

Read this article to find out the affect expedited regulatory approval (‘acceleration’) is having on the US...